nach oben

Current Atherosclerosis Reports

Erschienen in:

01.06.2011

Lecithin Cholesterol Acyltransferase: An Anti- or Pro-atherogenic Factor?

verfasst von: Xavier Rousset, Robert Shamburek, Boris Vaisman, Marcelo Amar, Alan T. Remaley

Erschienen in: Current Atherosclerosis Reports | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Lecithin cholesterol acyl transferase (LCAT) is a plasma enzyme that esterifies cholesterol and raises high-density lipoprotein cholesterol, but its role in atherosclerosis is not clearly established. Studies of various animal models have yielded conflicting results, but studies done in rabbits and non-human primates, which more closely simulate human lipoprotein metabolism, indicate that LCAT is likely atheroprotective. Although suggestive, there are also no biomarker studies that mechanistically link LCAT with cardiovascular disease. Imaging studies of patients with LCAT deficiency have also not yielded a clear answer to the role of LCAT in atherosclerosis. Recombinant LCAT, however, is currently being developed as a therapeutic product for enzyme replacement therapy of patients with genetic disorders of LCAT for the prevention and/or treatment of renal disease, but it may also have value for the treatment of acute coronary syndrome.

Rousset X, Vaisman B, Amar M, Sethi AA, Remaley AT. Lecithin: cholesterol acyltransferase–from biochemistry to role in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2009;16(2):163–71.PubMedCrossRef

Santamarina-Fojo S, Hoeg JM, Assmann G, H. Bryan Brewer J: Lecithin Cholesterol Acyltransferase Deficiency and Fish Eye Disease. In: Metabolic & Molecular Bases of Inherited Disease. 2001.

Chang T-Y, Li B-L, Chang CCY, Urano Y. Acyl-coenzyme A: cholesterol acyltransferases. Am J Physiol Endocrinol Metab. 2009;297(1):E1–9.PubMedCrossRef

Czarnecka H, Yokoyama S. Regulation of cellular cholesterol efflux by lecithin:cholesterol acyltransferase reaction through nonspecific lipid exchange. Journal of Biological Chemistry. 1996;271(4):2023–8.PubMedCrossRef

Nofer JR, Remaley A. Tangier disease: still more questions than answers. Cellular and Molecular Life Sciences. 2005;62(19):2150–60.PubMedCrossRef

Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscl Throm Vas. 2010;30(7):1430–U1405.CrossRef

Nishiwaki M, Ikewaki K, Bader G, et al. Human lecithin:cholesterol acyltransferase deficiency: in vivo kinetics of low-density lipoprotein and lipoprotein-X. Arterioscler Thromb Vasc Biol. 2006;26(6):1370–5.PubMedCrossRef

Lynn EG, Choy PC, Magil A. O K: uptake and metabolism of lipoprotein-X in mesangial cells. Mol Cell Biochem. 1997;175(1–2):187–94.PubMedCrossRef

Rader DJ. Lecithin: cholesterol acyltransferase and atherosclerosis: another high-density lipoprotein story that doesn’t quite follow the script. Circulation. 2009;120(7):549–52.PubMedCrossRef

10.

Greeve J, Altkemper I, Dieterich JH, Greten H, Windler E. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res. 1993;34(8):1367–83.PubMed

11.

Paigen B, Ishida BY, Verstuyft J, Winters RB, Albee D. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis. 1990;10(2):316–23.PubMed

12.

Berard AM, Foger B, Remaley A, et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med. 1997;3(7):744–9.PubMedCrossRef

13.

Foger B, Chase M, Amar MJ, et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem. 1999;274(52):36912–20.PubMedCrossRef

14.

Furbee Jr JW, Parks JS. Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition. Atherosclerosis. 2002;165(1):89–100.PubMedCrossRef

15.

Hoeg JM, Vaisman BL, Demosky Jr SJ, et al. Lecithin:cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem. 1996;271(8):4396–402.PubMedCrossRef

16.

Brousseau ME, Hoeg JM. Transgenic rabbits as models for atherosclerosis research. J Lipid Res. 1999;40(3):365–75.PubMed

17.

Brousseau ME, Santamarina-Fojo S, Vaisman BL, et al. Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner. J Lipid Res. 1997;38(12):2537–47.PubMed

18.

Sakai N, Vaisman BL, Koch CA, et al. Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene. Generation of a new animal model for human LCAT deficiency. J Biol Chem. 1997;272(11):7506–10.PubMedCrossRef

19.

Lambert G, Sakai N, Vaisman BL, et al. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. J Biol Chem. 2001;276(18):15090–8.PubMedCrossRef

20.

Ng DS, Maguire GF, Wylie J, et al. Oxidative stress is markedly elevated in lecithin:cholesterol acyltransferase-deficient mice and is paradoxically reversed in the apolipoprotein E knockout background in association with a reduction in atherosclerosis. J Biol Chem. 2002;277(14):11715–20.PubMedCrossRef

21.

Furbee Jr JW, Sawyer JK, Parks JS. Lecithin: cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice. J Biol Chem. 2002;277(5):3511–9.PubMedCrossRef

22.

Amar MJ, Shamburek RD, Vaisman B, et al. Adenoviral expression of human lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoprotein. Metabolism. 2009;58(4):568–75.PubMedCrossRef

23.

Zhou M, Sawyer J, Kelley K, et al: Abstract 5920: Lecithin Cholesterol Acyltransferase Promotes Reverse Cholesterol Transport and Attenuates Atherosclerosis Progression in New Zealand White Rabbits. Circulation 2009, 120(18_MeetingAbstracts):S1175-b-.

24.

Amar MJ, D'Souza W, Turner S, et al. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther. 2010;334(2):634–41.PubMedCrossRef

25.

Tanigawa H, Billheimer JT, Tohyama J, et al. Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation. 2009;120(2):160–9.PubMedCrossRef

26.

Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007;117(8):2216–24.PubMedCrossRef

27.

•• Sethi AA, Sampson M, Warnick R, et al. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem. 2010;56(7):1128–37. This work demonstrates that LCAT and pre-β are good biomarkers for cardiovascular disease. PubMedCrossRef

28.

Frohlich J, Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem. 2003;49(11):1873–80.PubMedCrossRef

29.

Dullaart RP, Perton F, Sluiter WJ, de Vries R, van Tol A. Plasma lecithin: cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. J Clin Endocrinol Metab. 2008;93(12):4860–6.PubMedCrossRef

30.

Dullaart RP, Perton F, Kappelle PJ, de Vries R, Sluiter WJ, van Tol A. Plasma lecithin: cholesterol acyltransferase activity modifies the inverse relationship of C-reactive protein with HDL cholesterol in nondiabetic men. Biochim Biophys Acta. 2010;1801(1):84–8.PubMed

31.

Hovingh GK, Hutten BA, Holleboom AG, et al. Compromised LCAT function is associated with increased atherosclerosis. Circulation. 2005;112(6):879–84.PubMedCrossRef

32.

Holleboom AG, Duivenvoorden R, van den Bogaard B, et al: Carriers of Lcat Gene Mutations Have Increased Atherosclerosis: A 3.0 Tesla Mri Study. Atherosclerosis Supp 2010, 11(2):61-61.

33.

Ayyobi AF, McGladdery SH, Chan S, John Mancini GB, Hill JS, Frohlich JJ. Lecithin: cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up. Atherosclerosis. 2004;177(2):361–6.PubMedCrossRef

34.

Calabresi L, Baldassarre D, Castelnuovo S, et al. Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation. 2009;120(7):628–35.PubMedCrossRef

35.

Wells IC, Peitzmeier G, Vincent JK. Lecithin: cholesterol acyltransferase and lysolecithin in coronary atherosclerosis. Exp Mol Pathol. 1986;45(3):303–10.PubMedCrossRef

36.

• Rousset X, Vaisman B, Auerbach B, et al: Effect of Recombinant Human Lecithin-cholesterol:acyltransferase Infusion on Lipoprotein Metabolism in Mice. J Pharmacol Exp Ther 2010. This work demonstates the feasibility of LCAT replacement therapy in the case of LCAT deficiency.

37.

Brady RO. Enzyme replacement for lysosomal diseases. Annu Rev Med. 2006;57:283–96.PubMedCrossRef

38.

Norum KR, Gjone E. The effect of plasma transfusion on the plasma cholesterol esters in patients with familial plasma lecithin: cholesterol acyltransferase deficiency. Scand J Clin Lab Invest. 1968;22(4):339–42.PubMedCrossRef

39.

Murayama N, Asano Y, Kato K, et al. Effects of plasma infusion on plasma lipids, apoproteins and plasma enzyme activities in familial lecithin: cholesterol acyltransferase deficiency. Eur J Clin Invest. 1984;14(2):122–9.PubMedCrossRef

40.

Klein HG, Santamarina-Fojo S, Duverger N, et al. Fish eye syndrome: a molecular defect in the lecithin-cholesterol acyltransferase (LCAT) gene associated with normal alpha-LCAT-specific activity. Implications for classification and prognosis. The Journal of Clinical Investigation. 1993;92(1):479–85.PubMedCrossRef

41.

Asada S, Kuroda M, Aoyagi Y, et al: Disturbed apolipoprotein A-I-containing lipoproteins in fish-eye disease are improved by the lecithin:cholesterol acyltransferase produced by gene-transduced adipocytes in vitro. Molecular Genetics and Metabolism, In Press.

42.

• Kuroda M, Aoyagi Y, Asada S, et al: Ceiling culture-derived proliferative adipocytes are a possible delivery vehicle for enzyme replacement therapy in lecithin:cholesterol acyltransferase deficiency. Gene Ther Mol Biol. In press. This article presents an alternative to LCAT injections for a treatment of the human LCAT deficiency.

43.

Remaley AT, Amar M, Sviridov D. HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev Cardiovasc Ther. 2008;6(9):1203–15.PubMedCrossRef

44.

Sethi AA, Amar M, Shamburek RD, Remaley AT. Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr Opin Investig Drugs. 2007;8(3):201–12.PubMed

45.

• Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010;328(5986):1689–93. This article presents new data on the interaction of HDL metabolism and blood cells. PubMedCrossRef

46.

Tardif JC, Heinonen T, Noble S. High-density lipoprotein/apolipoprotein A-I infusion therapy. Curr Atheroscler Rep. 2009;11(1):58–63.PubMedCrossRef

47.

Feister HA, Auerbach BJ, Cole LA, Krause BR, Karathanasis SK. Identification of an IL-6 response element in the human LCAT promoter. Journal of Lipid Research. 2002;43(6):960–70.PubMed

48.

Zhou M, Fordstrom P, Zhang J, et al. Novel small molecule LCAT activators raise HDL levels in rodent models. Arterioscl Throm Vas. 2008;28(6):E65–6.

49.

Vaisman BL, Klein HG, Rouis M, et al. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J Biol Chem. 1995;270(20):12269–75.PubMedCrossRef

50.

Mehlum A, Staels B, Duverger N, et al. Tissue-specific expression of the human gene for lecithin: cholesterol acyltransferase in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile. Eur J Biochem. 1995;230(2):567–75.PubMedCrossRef

51.

Van Craeyveld E, Lievens J, Jacobs F, Feng Y, Snoeys J, De Geest B. Apolipoprotein A-I and lecithin: cholesterol acyltransferase transfer induce cholesterol unloading in complex atherosclerotic lesions. Gene Ther. 2009;16(6):757–65.PubMedCrossRef

Titel: Lecithin Cholesterol Acyltransferase: An Anti- or Pro-atherogenic Factor?
verfasst von: Xavier Rousset
Robert Shamburek
Boris Vaisman
Marcelo Amar
Alan T. Remaley
Publikationsdatum: 01.06.2011
Verlag: Current Science Inc.
Erschienen in: Current Atherosclerosis Reports / Ausgabe 3/2011
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-011-0171-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Genetics of Redox Systems and Their Relationship with Cardiovascular Disease

Update on HDL Receptors and Cellular Cholesterol Transport

Genome-Wide Association Studies Complemented with Mechanistic Biological Studies Identify Sortilin 1 as a Novel Regulator of Cholesterol Trafficking

MicroRNAs in Cardiometabolic Disease

Genome-Wide Association Studies in Atherosclerosis